Talphera Inc
TLPH
查看详细走势图
1.100USD
-0.010-0.90%
收盘 12/19, 16:00（美东）报价延迟15分钟
50.14M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.90%
5天
-7.56%
1月
-16.03%
6月
+141.49%
今年开始到现在
+109.88%
1年
+73.15%
查看详细走势图
TradingKey Talphera Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Talphera Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在药品行业排名108/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.17。中期看，股价处于上升通道。近一个月，市场表现非常差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Talphera Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
4.167
目标均价
+223.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Talphera Inc亮点
亮点风险
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
估值低估
公司最新PE估值-2.91，处于3年历史低位
机构加仓
最新机构持股12.68M股，环比增加24.58%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值50.21K
活跃度增加
近期活跃度增加，过去20天平均换手率12.05
Talphera Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Talphera Inc简介
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
公司代码TLPH
公司Talphera Inc
CEOAngotti (Vincent J)
网址https://talphera.com/
常见问题
Talphera Inc(TLPH)的当前股价是多少？
Talphera Inc(TLPH)的当前股价是 1.100。
Talphera Inc的股票代码是什么？
Talphera Inc的股票代码是TLPH。
Talphera Inc股票的52周最高点是多少？
Talphera Inc股票的52周最高点是1.570。
Talphera Inc股票的52周最低点是多少？
Talphera Inc股票的52周最低点是0.380。
Talphera Inc的市值是多少？
Talphera Inc的市值是50.14M。
Talphera Inc的净利润是多少？
Talphera Inc的净利润为-13.00M。
现在Talphera Inc(TLPH)的股票是买入、持有还是卖出？
根据分析师评级，Talphera Inc(TLPH)的总体评级为买入，目标价格为4.167。
Talphera Inc(TLPH)股票的每股收益（EPS TTM）是多少
Talphera Inc(TLPH)股票的每股收益（EPS TTM）是-0.378。
相关品种
